The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects

Psychopharmacology

Volumn 137, Issue 3, 1998, Pages 271-281

  Van Berckel, B N M ^a   Oranje, B ^a   Van Ree, J M ^b   Verbaten, M N ^b   Kahn, R S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ketamine; NMDA; P50 reduction; Prepulse inhibition; Schizophrenia

Indexed keywords

HOMOVANILLIC ACID; HYDROCORTISONE; KETAMINE; LUTEINIZING HORMONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ADULT; ANALGESIA; ARTICLE; ATTENTION; CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVOKED RESPONSE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE RELEASE; INTRAVENOUS DRUG ADMINISTRATION; LUTEINIZING HORMONE RELEASE; MALE; MOOD; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STARTLE REFLEX; SYSTOLIC BLOOD PRESSURE; VISUAL HALLUCINATION;

ADULT; AROUSAL; ATTENTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; EXCITATORY AMINO ACID ANTAGONISTS; HOMOVANILLIC ACID; HUMANS; HYDROCORTISONE; KETAMINE; LUTEINIZING HORMONE; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; STARTLE REACTION;

EID: 0031808942     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050620     Document Type: Article

References (70)

1. Adler LE, Rose G, Freedman R (1986) Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol. Biol Psychiatry 21:786-798
2. Adler LE, Waldo MC, Tatcher A, Cawthra E, Baker N, Freedman R (1990) Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res 3:131-138
3. Andreasen NC (1985) Comprehensive assessment of symptoms and history (CASH). University of Iowa, Iowa City
4. Baker N, Adler LE, Franks RD, Waldo M, Berry S, Nagamoto H, Muckle A, Freedman R (1987) Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol Psychiatry 22:603-617
5. Bleuler E (1911) Dementia praecox or the group of schizophrenias. International Universities, New York
6. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218
7. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies [see comments]. Arch Gen Psychiatry 47:181-188
8. Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215
9. Brann DW (1995) Glutamate: a major excitatory transmitter in neuroendocrine regulation. Neuroendocrinology 61:213-225
10. Breier A, Malhotra AK, Pinals DA, Weisenfeld N, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805-811
11. Carlsson ML, Engberg G, Carlsson A (1994) Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J Neural Transm [Gen Sect] 95:223-233
12. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J, Adler LE, Freedman R (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 10: 131-141
13. Domino EF, Chodoff P, Corssen G (1965) Pharmacologic effects of Cl-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6:279-291
14. Endicott J, Spitzer RL (1978) Diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844
15. Ferin M, Carmel PW, Warren MP, Himsworth RL, Frantz AG, Nocenti MR (1976) Phencyclidine sedation as a technique for handling rhesus monkeys: effects on LH, GH, and prolactin secretion. Proc Soc Exp Biol Med 151:428-433
16. Freedman R, Mirsky AF (1991) Event-related potentials: exogenous components. In: Gruzelier JH, Zubin J (eds) Neuropsychology, psychophysiology, and information processing. Elsevier, Amsterdam, pp 71-90
17. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 18:537-551
18. Furuya Y, Ogura H (1997) Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol Biochem Behav 57:909-913
19. Geisslinger G, Menzel-Soglowek S, Kamp HD, Brune K (1991) Stereoselective high-performance liquid chromotographic determination of the enantiomers of ketamine and norketamine in plasma. J Chromatogr [Biomed Appl] 568:165-176
20. Goff DC, Tsai GC, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215
21. Grillon C, Ameli R, Charney DS, Krystal J, Braff D (1992) Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 32:939-943
22. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, Larue L (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 26:602-605
23. Harborne GC, Watson FL, Healy DT, Groves L (1996) The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 10:134-140
24. Hedlund JL, Vieweg BW (1980) The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Operational Psychiatry 11: 48-64
25. Irifune M, Shimizu T, Nomoto M, Fukuda T (1992) Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res 596:1-9
26. Jonkman LM, Kemner C, Verbaten MN, Koelega HS, Camfferman G, Gaag RJv, Buitelaar JK, van Engeland H (1997) Event-related potentials and performance of attention-deficit hyper-activity disorder children and normal controls in auditory and visual selctive attention tasks. Biol Psychiatry 41:595-611
27. Judd LJ, McAdams L, Budnick B, Braff DL (1992) Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 4:488-493
28. Kathmann N, Engel RR (1990) Sensory gating in normals and schizophrenics: a failure to find strong P50 suppression in normals. Biol Psychiatry 27:1216-1226
29. Keats AS, Telford J (1964) Narcotic antagonists as analgetics. Clinical aspects. In: Gould RF (ed) Molecular modification in drug design: advances in chemistry. American Chemical Society, Washington, DC, pp 170-176
30. Kenemans JL, Molenaar PC, Verbaten MN, Slangen JL (1991) Removal of the ocular artifacts from the EEG: a comparison of time and frequency domain methods with simulated and real data. Psychophysiologie 28:114-121
31. Kretschmer BD, Koch M (1997) Role of the strychnine insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology 130:131-138
32. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
33. Lahti AC, Koffel B, Laporte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
34. Lahti AC, Holcomb HH, Weiler MA, Zhao M, Medoff DR, Chen L, Tamminga CA (1997) Regional correlations between ketamine-induccd actions on psychosis and regional cerebral blood flow (rCBF). Schirophr Res Abstr 24:167-177
35. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of a new schizophrenomimetic drug Sernyl. AMA Arch Neurol Psychiatry 81:363-369
36. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962) Model psychoses and schizophrenia. Am J Psychiatry 119:61-67
37. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
38. Mansbach RS (1991) Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 202:61-66
39. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308
40. Mansbach RS, Geyer MA (1991) Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology 105:162-168
41. Mathiscn LC, Skjelbred P, Skoglund LA, Øve I (1995) Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 61:215-220
42. Maurset A, Skoglund LA, Hustveit O, Øye I (1989) Comparison of ketamine and pethidine in experimental and postoperative pain. Pain 36:37-41
43. McDowd JM, Filion DL, Harris MJ, Braff DL (1993) Sensory gating and inhibitory function in late-life schizophrenia. Schizophr Bull 19:733-746
44. McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103-116
45. McNair DM, Lorr M, Droppelman LF (1971) Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego
46. Nagamoto HT, Adler LE, Waldo MC, Freedman R (1989) Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 25:549-561
47. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R (1991) Gating of auditory response in schizophrenics and normal controls: effects of recording site and stimulation interval on the P50 wave. Schizophr Res 4:31-40
48. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812
49. Øye I, Hustveit O, Maurset A, Moberg E, Paulsen O, Skoglund LA (1991) The chiral forms of ketamine as probes for NMDA receptors in humans. In: Kameyama T, Nabeshima T, Domino EF (eds) NMDA related agents: biochemistry, pharmacology and behavior. NPP Books, Ann Arbor, pp 381-389
50. Øye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209-1213
51. Perry W, Braff DL (1994) Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 151: 363-367
52. Puri CP, Puri V, Anand Kumar TC (1981) Serum levels of testosterone, cortisol, prolactin and bioactive luteinizing hormone in adult male rhesus monkeys following cage-restraint or anaesthetizing with ketamine hydrochloride. Acta Endocrinol Copenh 97:118-124
53. Reijmers LGJE, Vanderheyden PML, Peeters BWMM (1995) Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur J Pharmacol 272:131-138
54. Rigby M, Lebourdelles B, Heavens RP, Kelly S, Smith D, Butler A, Hammans R, Hills R, Xuereb JH, Hill RO, Whiting PJ, Sirinathsinghji DJS (1996) The messenger RNAs for the N-methyl-D-aspartate receptor subunits show regio-specific expression of different subunit composition in the human brain. Neuroscience 73:429-447
55. Roth WT, Cannon EH (1995) Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry 27:466-471
56. Smith DJ, Pekoe GM, Martin LL, Coalgate B (1980) The interaction of ketamine with the opiate receptor. Life Sci 26:789-795
57. Sonders MS, Keana JFW, Weber E (1988) Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action. Trends Neurol Sci 11:37-40
58. Swerdlow NR, Caine SB, Braff DL, Geyer MA (1992) The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. J Psychopharmacol 6:176-190
59. Thijssen JH, Wood WG, Kessler AC, Griesser HW, Bauer O, Bieglmayer C, Eugui J, Mirabel JL, Gaessler H, Klinga K, Koettgen E, Mueller C, Messeri G, Neumeier D, Luppa D, Roger H, Castagnier M, Cervast G, Pernott P, Seth J, Gow S, Hanning J (1991) Multicenter evaluation of new enzyme-linked immunoassays of follitropin and lutropin in serum or plasma. Clin Chem 37:1257-1263
60. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
61. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52: 829-836
62. van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS (1996) Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298-1300
63. 2 receptor antagonist ketanserin. Eur J Pharmacol 287:201-205
64. Venables P (1964) Input dysfunction in schizophrenia. In: Maher BA (ed) Progress in experimental personality research. Academic Press, New York, pp 1-47
65. Vollenweider FX, Leenders KL, Øye I, Hell D, Angst J (1997a) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25-38
66. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997b) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9-24
67. Wald FDM, Mellenbergh GJ (1990) De verkorte versie van de nederlandse vertaling van de Profile Of Mood States (POMS). Ned T Psychol 45:86-90
68. Waldo MC, Adler LE, Freedman R (1988) Defects in auditory sensory gating and their apparent compensation in relatives of schizophrenics. Schizophr Res 1:19-24
69. Wedzony K, Golembiowska K, Zazula M (1994) Differential effects of CGP 37849 and MK-801, competitive and noncompetative NMDA antagonists, with respect to modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn-Schmiedeberg's Arch Pharmacol 350: 555-562
70. Westenberg HGM, Verhoeven WMA (1988) CSF monoamine metabolites in dementia of altzheimer type and controls: evidence for lower level of homovanillic acid and 5-hydroxyindole acetic acid in patients. Int J Geriatr Psychiatry 3:281-288